Approximately 30%-40%of individuals with diabetes develop chronic kidney disease during their lifetime,and patients with type 2 diabetes mellitus have a high risk of developing and progressing to this condition.The tw...Approximately 30%-40%of individuals with diabetes develop chronic kidney disease during their lifetime,and patients with type 2 diabetes mellitus have a high risk of developing and progressing to this condition.The two comorbidities represent a lethal combination that exacerbates both diseases.It is crucial to measure the glomerular filtration rate and to monitor and assess the renal functionality of these patients.Serum creatinine,the traditional marker of kidney assessment,has been shown to be susceptible to too many variables that can significantly alter the final estimated glomerular filtration rate outcome.Cystatin C-based formulas appear to have reasonable accuracy in this population and help to ensure better tailored therapy and renal assessment.The purpose of this editorial was to provide an examination of the advantage of using cystatin C as a valid marker for determining estimated glomerular filtration rate,free from any interfering factors,allowing a more accurate assessment of renal function.展开更多
背景与目的探讨cystatin M基因在人乳腺癌组织中的表达及生物学意义。材料与方法采用半定量RT-PCR方法和免疫组织化学法检测50例乳腺癌组织和配对癌旁乳腺组织半胱氨酸蛋白酶抑制剂cystatin M mRNA和蛋白表达及其与临床病理特征的关系...背景与目的探讨cystatin M基因在人乳腺癌组织中的表达及生物学意义。材料与方法采用半定量RT-PCR方法和免疫组织化学法检测50例乳腺癌组织和配对癌旁乳腺组织半胱氨酸蛋白酶抑制剂cystatin M mRNA和蛋白表达及其与临床病理特征的关系。结果乳腺癌组织cystatin M mRNA表达阳性率为62%(31/50),其配对癌旁乳腺组织为94%(47/50),在乳腺癌细胞系MDA-MB-435S中未见其表达。乳腺癌组织cystatin M mRNA的表达指数为0.412±0.021,明显低于配对的癌旁乳腺组织(0.541±0.020),二者差异有统计学意义(P<0.01)。cystatin M蛋白在乳腺癌及癌旁组织表达阳性率分别为58%(29/50)和92%(46/50);其平均光密度值为0.318±0.058,显著低于癌旁乳腺组织(0.428±0.064,P<0.01);cystatin M表达下调与乳腺癌淋巴结转移和临床TNM分期显著相关(P<0.05),而与肿瘤的大小、病理分级、ER和PR状况无关(P>0.05)。结论人乳腺癌组织存在cystatin M基因表达显著下调且与肿瘤的浸润和转移有关。展开更多
文摘Approximately 30%-40%of individuals with diabetes develop chronic kidney disease during their lifetime,and patients with type 2 diabetes mellitus have a high risk of developing and progressing to this condition.The two comorbidities represent a lethal combination that exacerbates both diseases.It is crucial to measure the glomerular filtration rate and to monitor and assess the renal functionality of these patients.Serum creatinine,the traditional marker of kidney assessment,has been shown to be susceptible to too many variables that can significantly alter the final estimated glomerular filtration rate outcome.Cystatin C-based formulas appear to have reasonable accuracy in this population and help to ensure better tailored therapy and renal assessment.The purpose of this editorial was to provide an examination of the advantage of using cystatin C as a valid marker for determining estimated glomerular filtration rate,free from any interfering factors,allowing a more accurate assessment of renal function.
文摘背景与目的探讨cystatin M基因在人乳腺癌组织中的表达及生物学意义。材料与方法采用半定量RT-PCR方法和免疫组织化学法检测50例乳腺癌组织和配对癌旁乳腺组织半胱氨酸蛋白酶抑制剂cystatin M mRNA和蛋白表达及其与临床病理特征的关系。结果乳腺癌组织cystatin M mRNA表达阳性率为62%(31/50),其配对癌旁乳腺组织为94%(47/50),在乳腺癌细胞系MDA-MB-435S中未见其表达。乳腺癌组织cystatin M mRNA的表达指数为0.412±0.021,明显低于配对的癌旁乳腺组织(0.541±0.020),二者差异有统计学意义(P<0.01)。cystatin M蛋白在乳腺癌及癌旁组织表达阳性率分别为58%(29/50)和92%(46/50);其平均光密度值为0.318±0.058,显著低于癌旁乳腺组织(0.428±0.064,P<0.01);cystatin M表达下调与乳腺癌淋巴结转移和临床TNM分期显著相关(P<0.05),而与肿瘤的大小、病理分级、ER和PR状况无关(P>0.05)。结论人乳腺癌组织存在cystatin M基因表达显著下调且与肿瘤的浸润和转移有关。
